IP Library › Granted Patent US 12,466,841
Granted Patent B2
US 12,466,841 · App. 18/536,817 · Granted Nov 11, 2025

Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists

Inventors: Neelu Kaila (Lexington, MA); Ian Linney (Saffron Walden, GB); Stuart Ward (Saffron Walden, GB); Grant Wishart (Saffron Walden, GB); Benjamin Whittaker (Saffron Walden, GB); Alexandre Cote (West New York, NJ); Jeremy Robert Greenwood (Brooklyn, NY); Abba Leffler (Bronx, NY)
Assignee: Nimbus Saturn, Inc.
C07D519/00C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,841
App. No.
18/536,817
Granted
Nov 11, 2025
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Claims (154)

1 . A method for inhibiting hematopoietic progenitor kinase 1 (HPK1) activity in a patient, wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,

wherein:

X is —NR—;

R 1 is a 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 8- to 10-membered heterocyclyl is bicyclic and saturated or partially unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 8- to 10-membered heterocyclyl or 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents;

R 2 is a 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 6- to 11-membered cyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 6- to 11-membered cyclyl is (a) bicyclic, (b) fused, bridged, or spirocyclic, and (c) saturated, partially unsaturated, or fully unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 6- to 11-membered cyclyl contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 6- to 11-membered cyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents;

each R 3 is independently H or C 1-6 aliphatic, wherein the C 1-6 aliphatic is substituted with s independently selected R D substituents;

each R C is independently halogen, CN, NO 2 , C 1-6 aliphatic, C(O)R, C(O)NR 2 , C(O)NROR, C(O)OR, NR 2 , NRC(NR)NR 2 , NRCN, NRC(O)R, NRC(O)NR 2 , NRC(O)OR, NRNR 2 , NRS(O)R, NRS(O) 2 R, NRS(O) 2 NR 2 , N═S(O)R 2 , OR, OC(O)R, OC(O)NR 2 , ═O, P(O)R 2 , P(O)RNR 2 , P(O)ROR, SR, S(O)R, S(O)NR 2 , S(NR)(O)R, S(O) 2 R, S(O) 2 NR 2 , 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 11-membered cyclyl, 6- to 11-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl;

wherein each 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is independently monocyclic and saturated or partially unsaturated;

wherein each 5- to 8-membered cyclyl is independently (a) bicyclic, (b) bridged, and (c) saturated or partially unsaturated;

wherein each 6- to 11-membered cyclyl is independently spirocyclic and saturated or partially unsaturated;

wherein each 6- to 11-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 5- or 6-membered heteroaryl is independently monocyclic;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 3- to 7-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, P, Si, and S;

wherein each 5- to 8-membered cyclyl and 6- to 11-membered cyclyl independently contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 6- to 11-membered heterocyclyl independently contains 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 5- or 6-membered heteroaryl independently contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 8- to 10-membered heteroaryl independently contains 1, 2, 3, 4, or 5 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 11-membered cyclyl, 6- to 11-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, and 8- to 10-membered heteroaryl is independently substituted with r independently selected R substituents and s independently selected R D substituents;

each R is independently H, halogen, CN, C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 10-membered cyclyl, 6- to 11-membered heterocyclyl, 7- to 12-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl;

wherein each 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is independently monocyclic and saturated or partially unsaturated;

wherein each 5- to 8-membered cyclyl is independently (a) bicyclic, (b) bridged, and (c) saturated or partially unsaturated;

wherein each 6- to 10-membered cyclyl is independently spirocyclic and saturated or partially unsaturated;

wherein each 6- to 11-membered heterocyclyl and 7- to 12-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 5- or 6-membered heteroaryl is independently monocyclic;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 3- to 7-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 5- to 8-membered cyclyl and 6- to 10-membered cyclyl independently contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 6- to 11-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 7- to 12-membered heterocyclyl, 5- or 6-membered heteroaryl, and 8- to 10-membered heteroaryl independently contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 10-membered cyclyl, 6- to 11-membered heterocyclyl, 7- to 12-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl is independently substituted with s independently selected R D substituents; or

any two R substituents, together with the nitrogen heteroatom to which they are attached, independently forms a 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, or 8- to 10-membered heteroaryl;

wherein each 4- to 7-membered heterocyclyl is independently monocyclic and saturated, partially unsaturated, or fully saturated;

wherein each 7- to 12-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, and 8- to 10-membered heteroaryl optionally and independently contains 1, 2, or 3 additional heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, and 8- to 10-membered heteroaryl is independently substituted with s independently selected R D substituents;

each R D is independently halogen, CN, NO 2 , C(O)R, C(O)NR 2 , C(O)NROR, C(O)OR, NR 2 , NRC(NR)NR 2 , NRCN, NRC(O)R, NRC(O)NR 2 , NRC(O)OR, NRNR 2 , NRS(O)R, NRS(O) 2 R, NRS(O) 2 NR 2 , N═S(O)R 2 , OR, OC(O)R, OC(O)NR 2 , ═O, P(O)R 2 , P(O)RNR 2 , P(O)ROR, SR, S(O)R, S(O)NR 2 , S(NR)(O)R, S(O) 2 R, or S(O) 2 NR 2 ;

each q is independently 0, 1, 2, 3, or 4;

r is 0, 1, 2, 3, or 4; and

s is 0, 1, 2, 3, or 4.

2 . The method of claim 1 , wherein the patient has a hematopoietic progenitor kinase 1 (HPK1)-mediated proliferative disorder, proliferative disease, or proliferative condition.

3 . The method of claim 2 , wherein the hematopoietic progenitor kinase 1 (HPK1)-mediated proliferative disorder, proliferative disease, or proliferative condition is associated with one or more activating mutations in hematopoietic progenitor kinase 1 (HPK1).

4 . The method of claim 2 , wherein the hematopoietic progenitor kinase 1 (HPK1)-mediated proliferative disorder, proliferative disease, or proliferative condition is cancer.

5 . The method of claim 4 , wherein the cancer is selected from the group consisting of a hematological malignancy, breast cancer, colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and renal cell carcinoma.

6 . The method of claim 4 , wherein the cancer is a hematological cancer or a solid tumor.

7 . The method of claim 6 , wherein the solid tumor is selected from the group consisting of bladder cancer, breast cancer, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, glioblastoma, head and neck cancer, hepatic cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, thyroid cancer, and uterine cancer.

8 . The method of claim 1 , wherein X is —NH—.

9 . The method of claim 1 , wherein R 1 is 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 8- to 10-membered heterocyclyl is bicyclic and saturated or partially unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 8- to 10-membered heterocyclyl or 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents.

10 . The method of claim 1 , wherein R 1 is phenyl or 5- or 6-membered heteroaryl;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the phenyl or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents.

11 . The method of claim 1 , wherein R 1 is phenyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyrazinyl;

wherein the phenyl, pyrazolyl, pyridinyl, pyrimidinyl, or pyrazinyl is substituted with q independently selected R C substituents.

12 . The method of claim 1 , wherein R 1 is:

13 . The method of claim 1 , wherein R 1 is:

14 . The method of claim 1 , wherein R 2 is 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents.

15 . The method of claim 1 , wherein R 2 is cyclopropyl, tetrahydropyranyl, morpholinyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyridazinyl, or pyrimidinyl, wherein the cyclopropyl, tetrahydropyranyl, morpholinyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyridazinyl, or pyrimidinyl is substituted with q independently selected R C substituents.

16 . The method of claim 1 , wherein R 2 is:

17 . The method of claim 1 , wherein R 2 is:

18 . The method of claim 1 , wherein R 2 is a 6- to 11-membered cyclyl;

wherein the 6- to 11-membered cyclyl is (a) bicyclic, (b) fused, bridged, or spirocyclic, and (c) saturated, partially unsaturated, or fully unsaturated;

wherein the 6- to 11-membered cyclyl contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 6- to 11-membered cyclyl is substituted with q independently selected R C substituents.

19 . The method of claim 1 , wherein R 2 is a 9-membered heterocyclyl;

wherein the 9-membered heterocyclyl is (a) bicyclic, (b) fused, and (c) saturated, partially unsaturated, or fully unsaturated;

wherein the 9-membered heterocyclyl contains 1, 2, or 3 N heteroatoms; and

wherein the 9-membered heterocyclyl is substituted with q independently selected R C substituents.

20 . The method of claim 1 , wherein R 2 is:

21 . The method of claim 1 , wherein R 2 is:

22 . The method of claim 1 , wherein each R 3 is independently H or C 1-4 aliphatic, wherein the C 1-4 aliphatic is substituted with s independently selected R D substituents.

23 . The method of claim 1 , wherein the compound, or stereoisomer thereof, is selected from the group consisting of:

or a pharmaceutically acceptable salt or tautomer thereof.

24 . A method for inhibiting hematopoietic progenitor kinase 1 (HPK1) activity in a patient, wherein the method comprises administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle and a compound of formula I:

or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof,

wherein:

X is —NR—;

R 1 is a 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 8- to 10-membered heterocyclyl is bicyclic and saturated or partially unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 8- to 10-membered heterocyclyl or 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 8- to 10-membered heterocyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents;

R 2 is a 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 6- to 11-membered cyclyl, phenyl, or 5- or 6-membered heteroaryl;

wherein the 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is monocyclic and saturated or partially unsaturated;

wherein the 6- to 11-membered cyclyl is (a) bicyclic, (b) fused, bridged, or spirocyclic, and (c) saturated, partially unsaturated, or fully unsaturated;

wherein the 5- or 6-membered heteroaryl is monocyclic;

wherein the 3- to 7-membered heterocyclyl contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 6- to 11-membered cyclyl contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein the 5- or 6-membered heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein the 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 6- to 11-membered cyclyl, phenyl, or 5- or 6-membered heteroaryl is substituted with q independently selected R C substituents;

each R 3 is independently H or C 1-6 aliphatic, wherein the C 1-6 aliphatic is substituted with s independently selected R D substituents;

each R C is independently halogen, CN, NO 2 , C 1-6 aliphatic, C(O)R, C(O)NR 2 , C(O)NROR, C(O)OR, NR 2 , NRC(NR)NR 2 , NRCN, NRC(O)R, NRC(O)NR 2 , NRC(O)OR, NRNR 2 , NRS(O)R, NRS(O) 2 R, NRS(O) 2 NR 2 , N═S(O)R 2 , OR, OC(O)R, OC(O)NR 2 , ═O, P(O)R 2 , P(O)RNR 2 , P(O)ROR, SR, S(O)R, S(O)NR 2 , S(NR)(O)R, S(O) 2 R, S(O) 2 NR 2 , 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 11-membered cyclyl, 6- to 11-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl;

wherein each 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is independently monocyclic and saturated or partially unsaturated;

wherein each 5- to 8-membered cyclyl is independently (a) bicyclic, (b) bridged, and (c) saturated or partially unsaturated;

wherein each 6- to 11-membered cyclyl is independently spirocyclic and saturated or partially unsaturated;

wherein each 6- to 11-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 5- or 6-membered heteroaryl is independently monocyclic;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 3- to 7-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, P, Si, and S;

wherein each 5- to 8-membered cyclyl and 6- to 11-membered cyclyl independently contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 6- to 11-membered heterocyclyl independently contains 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 5- or 6-membered heteroaryl independently contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 8- to 10-membered heteroaryl independently contains 1, 2, 3, 4, or 5 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 11-membered cyclyl, 6- to 11-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, and 8- to 10-membered heteroaryl is independently substituted with r independently selected R substituents and s independently selected R D substituents;

each R is independently H, halogen, CN, C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 10-membered cyclyl, 6- to 11-membered heterocyclyl, 7- to 12-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl;

wherein each 3- to 7-membered carbocyclyl or 3- to 7-membered heterocyclyl is independently monocyclic and saturated or partially unsaturated;

wherein each 5- to 8-membered cyclyl is independently (a) bicyclic, (b) bridged, and (c) saturated or partially unsaturated;

wherein each 6- to 10-membered cyclyl is independently spirocyclic and saturated or partially unsaturated;

wherein each 6- to 11-membered heterocyclyl and 7- to 12-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 5- or 6-membered heteroaryl is independently monocyclic;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 3- to 7-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 5- to 8-membered cyclyl and 6- to 10-membered cyclyl independently contains 0, 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 6- to 11-membered heterocyclyl independently contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;

wherein each 7- to 12-membered heterocyclyl, 5- or 6-membered heteroaryl, and 8- to 10-membered heteroaryl independently contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each C 1-6 aliphatic, 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, 5- to 8-membered cyclyl, 6- to 10-membered cyclyl, 6- to 11-membered heterocyclyl, 7- to 12-membered heterocyclyl, phenyl, naphthalenyl, 5- or 6-membered heteroaryl, or 8- to 10-membered heteroaryl is independently substituted with s independently selected R D substituents; or

any two R substituents, together with the nitrogen heteroatom to which they are attached, independently forms a 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, or 8- to 10-membered heteroaryl;

wherein each 4- to 7-membered heterocyclyl is independently monocyclic and saturated, partially unsaturated, or fully saturated;

wherein each 7- to 12-membered heterocyclyl is independently bicyclic and saturated or partially unsaturated;

wherein each 8- to 10-membered heteroaryl is independently bicyclic;

wherein each 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, and 8- to 10-membered heteroaryl optionally and independently contains 1, 2, or 3 additional heteroatoms independently selected from the group consisting of N, O, and S; and

wherein each 4- to 7-membered heterocyclyl, 7- to 12-membered heterocyclyl, and 8- to 10-membered heteroaryl is independently substituted with s independently selected R D substituents;

each R D is independently halogen, CN, NO 2 , C(O)R, C(O)NR 2 , C(O)NROR, C(O)OR, NR 2 , NRC(NR)NR 2 , NRCN, NRC(O)R, NRC(O)NR 2 , NRC(O)OR, NRNR 2 , NRS(O)R, NRS(O) 2 R, NRS(O) 2 NR 2 , N═S(O)R 2 , OR, OC(O)R, OC(O)NR 2 , ═O, P(O)R 2 , P(O)RNR 2 , P(O)ROR, SR, S(O)R, S(O)NR 2 , S(NR)(O)R, S(O) 2 R, or S(O) 2 NR 2 ;

each q is independently 0, 1, 2, 3, or 4;

r is 0, 1, 2, 3, or 4; and

s is 0, 1, 2, 3, or 4.

Assignments (14)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 67428 FRAME: 677. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 7, 2024
From: LINNEY, IAN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 068480/0799 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: LINNEY, IAN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 067428/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: WARD, STUART
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 067428/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: WHITTAKER, BENJAMIN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 067428/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: WISHART, GRANT
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 067428/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 067428/0693 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: LEFFLER, ABBA
To: SCHRÖDINGER, INC.
Reel/Frame 067428/0737 →
EMPLOYMENT AGREEMENT Recorded May 15, 2024
From: GREENWOOD, JEREMY ROBERT
To: SCHRÖDINGER, INC.
Reel/Frame 067428/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: CHARLES RIVER LABORATORIES, INC.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 067428/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, L.L.C.
Reel/Frame 067428/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: SCHRÖDINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 067428/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: NIMBUS DISCOVERY, INC.
To: NIMBUS SATURN, INC.
Reel/Frame 067428/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: KAILA, NEELU
To: NIMBUS DISCOVERY, INC.
Reel/Frame 067588/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2024
From: COTE, ALEXANDRE
To: SCHRÖDINGER, INC.
Reel/Frame 067428/0741 →
Continuity (4)
Division 17656924 · Mar 29, 2022
Provisional Application 63182313 · Apr 30, 2021
Provisional Application 63167455 · Mar 29, 2021
Related Publication 20240190895A1 · Jun 13, 2024
References Cited (187)
US 2475569A · Halley · 1949 [cited by applicant]
US 4650750A · Giese · 1987 [cited by applicant]
US 4709016A · Giese · 1987 [cited by applicant]
US 5360819A · Giese · 1994 [cited by applicant]
US 5516931A · Giese et al. · 1996 [cited by applicant]
US 5602273A · Giese et al. · 1997 [cited by applicant]
US 5604104A · Giese et al. · 1997 [cited by applicant]
US 5610020A · Giese et al. · 1997 [cited by applicant]
US 5650270A · Giese et al. · 1997 [cited by applicant]
US 7081449B2 · Pietrzkowski et al. · 2006 [cited by applicant]
US 7390799B2 · Bruncko et al. · 2008 [cited by applicant]
US 7745641B2 · Murakata et al. · 2010 [cited by applicant]
US 8138347B2 · Knight et al. · 2012 [cited by applicant]
US 8546370B2 · Okram et al. · 2013 [cited by applicant]
US 8796313B2 · Dudash et al. · 2014 [cited by applicant]
US 8906682B2 · June et al. · 2014 [cited by applicant]
US 8969565B2 · Bi et al. · 2015 [cited by applicant]
US 11021481B2 · Kaila et al. · 2021 [cited by applicant]
US 11028085B2 · Kaila et al. · 2021 [cited by applicant]
US 11034694B2 · Kaila et al. · 2021 [cited by applicant]
US 11078201B2 · Kaila et al. · 2021 [cited by applicant]
US 11548890B1 · Kaila et al. · 2023 [cited by applicant]
US 11926625B2 · Kaila et al. · 2024 [cited by applicant]
US 20050026976A1 · Curtin et al. · 2005 [cited by applicant]
US 20060287370A1 · Curtin et al. · 2006 [cited by applicant]
US 20100179153A1 · Mattes et al. · 2010 [cited by applicant]
US 20110245247A1 · Braje et al. · 2011 [cited by applicant]
US 20140171429A1 · Vasudevan et al. · 2014 [cited by applicant]
US 20150336934A1 · Hong et al. · 2015 [cited by applicant]
US 20160297815A1 · Choi et al. · 2016 [cited by applicant]
US 20160311772A1 · Choi et al. · 2016 [cited by applicant]
US 20170226129A1 · Yu et al. · 2017 [cited by applicant]
US 20180127396A1 · Li et al. · 2018 [cited by applicant]
US 20180141951A1 · Arikawa et al. · 2018 [cited by applicant]
US 20180179221A1 · Sampson et al. · 2018 [cited by applicant]
US 20180282318A1 · Cremonesi et al. · 2018 [cited by applicant]
US 20180282328A1 · Chan et al. · 2018 [cited by applicant]
US 20180344702A1 · Rice et al. · 2018 [cited by applicant]
US 20190256500A1 · Vechorkin et al. · 2019 [cited by applicant]
US 20190256520A1 · Sokolsky et al. · 2019 [cited by applicant]
US 20200000780A1 · Heffron et al. · 2020 [cited by applicant]
US 20200017511A1 · Blank et al. · 2020 [cited by applicant]
US 20200038378A1 · Crew et al. · 2020 [cited by applicant]
US 20200190104A1 · Sampson et al. · 2020 [cited by applicant]
US 20200237025A1 · Su · 2020 [cited by applicant]
US 20210078996A1 · Kaila et al. · 2021 [cited by applicant]
US 20210078997A1 · Kaila et al. · 2021 [cited by applicant]
US 20210078998A1 · Kaila et al. · 2021 [cited by applicant]
US 20210087189A1 · Kaila et al. · 2021 [cited by applicant]
US 20210087190A1 · Kaila et al. · 2021 [cited by applicant]
US 20220363695A1 · Kaila et al. · 2022 [cited by applicant]
CA 2988721A1 · 2018 [cited by applicant]
CN 109721620A · 2019 [cited by applicant]
CN 111961035A · 2020 [cited by applicant]
EP 1477472B1 · 2009 [cited by applicant]
EP 2108642A1 · 2009 [cited by applicant]
JP 2008510765A · 2008 [cited by applicant]
JP 2012528864A · 2012 [cited by applicant]
JP 2018522858A · 2018 [cited by applicant]
WO WO2001042246A2 · 2001 [cited by applicant]
WO WO2002088112A1 · 2002 [cited by applicant]
WO WO2003063794A2 · 2003 [cited by applicant]
WO WO2004019973A1 · 2004 [cited by applicant]
WO WO2004089925A1 · 2004 [cited by applicant]
WO WO2004106328A1 · 2004 [cited by applicant]
WO WO2005007623A2 · 2005 [cited by applicant]
WO 2005056524A2 · 2005 [cited by applicant]
WO WO2005113554A2 · 2005 [cited by applicant]
WO 200621457A2 · 2006 [cited by applicant]
WO WO2006029879A2 · 2006 [cited by applicant]
WO WO2006078846A1 · 2006 [cited by applicant]
WO WO2006105021A2 · 2006 [cited by applicant]
WO WO2006122806A2 · 2006 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2007016176A2 · 2007 [cited by applicant]
WO WO2007044729A2 · 2007 [cited by applicant]
WO WO2007053452A1 · 2007 [cited by applicant]
WO WO2007070514A1 · 2007 [cited by applicant]
WO WO2007084786A1 · 2007 [cited by applicant]
WO WO2007129161A2 · 2007 [cited by applicant]
WO WO2020089026A2 · 2008 [cited by applicant]
WO 2008047831A1 · 2008 [cited by applicant]
WO WO2008039218A2 · 2008 [cited by applicant]
WO WO2008109943A1 · 2008 [cited by applicant]
WO WO2008118802A1 · 2008 [cited by applicant]
WO WO2008132601A1 · 2008 [cited by applicant]
WO WO2009009116A2 · 2009 [cited by applicant]
WO WO2009044273A2 · 2009 [cited by applicant]
WO WO2009073620A2 · 2009 [cited by applicant]
WO WO2009074812A1 · 2009 [cited by applicant]
WO 2009097287A1 · 2009 [cited by applicant]
WO 2009099801A1 · 2009 [cited by applicant]
WO WO2009114512A1 · 2009 [cited by applicant]
WO WO2009156652A1 · 2009 [cited by applicant]
WO WO2010019570A2 · 2010 [cited by applicant]
WO WO2010077634A1 · 2010 [cited by applicant]
WO WO2010141406A2 · 2010 [cited by applicant]
WO 2011014515A1 · 2011 [cited by applicant]
WO 2011014795A2 · 2011 [cited by applicant]
WO WO2011028683A1 · 2011 [cited by applicant]
WO WO2011056652A1 · 2011 [cited by applicant]
WO WO2011070024A1 · 2011 [cited by applicant]
WO WO2011090760A1 · 2011 [cited by applicant]
WO WO2011107553A1 · 2011 [cited by applicant]
WO WO2011109400A2 · 2011 [cited by applicant]
WO WO2011131407A1 · 2011 [cited by applicant]
WO WO2011140249A2 · 2011 [cited by applicant]
WO WO2012032433A1 · 2012 [cited by applicant]
WO 2012097479A1 · 2012 [cited by applicant]
WO 2012142237A1 · 2012 [cited by applicant]
WO WO2012145493A1 · 2012 [cited by applicant]
WO WO2013079174A1 · 2013 [cited by applicant]
WO WO2013086397A1 · 2013 [cited by applicant]
WO WO2013087699A1 · 2013 [cited by applicant]
WO WO2013119716A1 · 2013 [cited by applicant]
WO WO2013132044A1 · 2013 [cited by applicant]
WO WO2013169264A1 · 2013 [cited by applicant]
WO WO2014008218A1 · 2014 [cited by applicant]
WO WO2014036357A1 · 2014 [cited by applicant]
WO WO2014074660A1 · 2014 [cited by applicant]
WO WO2014074661A1 · 2014 [cited by applicant]
WO WO2014142237A1 · 2014 [cited by applicant]
WO WO2015089143A1 · 2015 [cited by applicant]
WO WO2015131080A1 · 2015 [cited by applicant]
WO WO2016106106A2 · 2016 [cited by applicant]
WO 2016205942A1 · 2016 [cited by applicant]
WO 2017147328A1 · 2017 [cited by applicant]
WO 2018049152A1 · 2018 [cited by applicant]
WO 2018068017A1 · 2018 [cited by applicant]
WO 2018102366A1 · 2018 [cited by applicant]
WO 2018167147A1 · 2018 [cited by applicant]
WO 2018183956A1 · 2018 [cited by applicant]
WO 2018183964A1 · 2018 [cited by applicant]
WO 2019070742A1 · 2019 [cited by applicant]
WO 2019090198A1 · 2019 [cited by applicant]
WO 2019238424A1 · 2019 [cited by applicant]
WO 2020073945A1 · 2020 [cited by applicant]
WO 2020100027A1 · 2020 [cited by applicant]
WO 2020106307A1 · 2020 [cited by applicant]
WO 2020237025A1 · 2020 [cited by applicant]
WO 2021000935A1 · 2021 [cited by applicant]
WO WO2021050964A1 · 2021 [cited by applicant]
WO 2021222556A1 · 2021 [cited by applicant]
WO 2021262684A1 · 2021 [cited by applicant]
WO WO2022213062A1 · 2022 [cited by applicant]
Jordan, V. C. Nature Reviews: Drug Discovery, Feb. 2003, 205. [cited by examiner]
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. [cited by examiner]
Martin et al., “Flow synthesis of annulated 5-aryl-substituted pyridines by tandem intramolecular inverse-electron-demand hetero-/retro-Diels—Alder reaction,” Tetrahedron Letters 2013; 54(49): 6703-6707. [cited by applicant]
Adams et al., “Big opportunities for small molecules in immuno-oncology,” Cancer Therapy. 2015; 14: 603-622. [cited by applicant]
Berge et al., “Pharmaceutical salts,” J. Pharmaceutical Sciences 1977; 66(1):1-19. [cited by applicant]
Di Bartolo et al. A novel pathway down-modulating T cell activation involves HPK-1-dependent recruitment of 14-3-3 proteins on SLP-76, J Exp Med. 2007; 204(3): 681-691. [cited by applicant]
Hu et al., “Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade,” Genes Dev. 1996; 10(18): 2251-64. [cited by applicant]
Ikegami et al., “The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages,” J Immunol. 2001; 166(7): 4689-96. [cited by applicant]
Kiefer et al., “HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway,” EMBO J. 1996; 15(24): 7013-25. [cited by applicant]
Lasserre et al., “Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation,” J Cell Biol. 2011; 195(5): 839-853. [cited by applicant]
Liou et al., “HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1,” Immunity. 2000; 12(4): 399-408. [cited by applicant]
Okazaki et al., “A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application,” Nat. Immunol. 2013; 14(12): 1212-1218. [cited by applicant]
PCT International Search Report from PCT/US2020/050524 dated Oct. 31, 2020. [cited by applicant]
PCT International Search Report from PCT/US2022/070627 dated Jun. 6, 2022. [cited by applicant]
PCT International Search Report from PCT/US2022/071403 dated Jun. 6, 2022. [cited by applicant]
PubChem—SID-369999312, Modify Date: May 28, 2018. [cited by applicant]
PubChem—SID-132639281, Modify Date: May 31, 2019. [cited by applicant]
Ramirez et al “Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma” Leuk. Res. (Jul. 17, 2012), published online. [cited by applicant]
Ross et al., “Bispecific T cell engager (BITE®) antibody constructs can mediate bystander tumor cell killing,” PLoS One. 2017; 12(8): e0183390. [cited by applicant]
Rostovtsev et al., “A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes,” Angew. Chem. Int. Ed., 2002, vol. 41, pp. 2596-2599. [cited by applicant]
Shui et al., “Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses,” Nat Immunol. 2007; 8(1): 84-91. [cited by applicant]
Sun et al., “Carbohydrate and protein immobilization onto solid surfaces by sequential Diels-Alder and azide-alkyne cycloadditions,” Bioconjugate Chem., 2006, vol. 17, No. 1, pp. 52-57. [cited by applicant]
Toogood, “Small molecule immuno-oncology therapeutic agents,” Bioorganic & Medicinal Chemistry Letters. 2018; 28(3): 319-329. [cited by applicant]
Wang et al., “Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase … [cited by applicant]
Wang et al., “Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK),” J Biol Chem. 2012; 287(14): … [cited by applicant]
Zhou et al., “Hematopoietic progenitor kinase 1 is a component of transforming growth factor beta-induced c-Jun N-terminal kinase signaling cascade,” J Biol Chem. 1999; 274(19): 13133-8. [cited by applicant]
Zou et al., “PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations,” Sci. Transl. Med. 2016; 8(328): 1-14. [cited by applicant]
Deguest et al., “One-Pot Synthesis of 2,3-Dihydro-pyrrolopyridinones Using in Situ Generated Formimines,” Organic Letters. 2006; 8(25):5889-92. [cited by applicant]
PCT International Search Report from PCT/US2022/070970 dated Jul. 14, 2022. [cited by applicant]
Pubchem—CID-14005627, Modify Date: Feb. 9, 2007. [cited by applicant]
Hensbergen, et al, “An expedient synthesis of oxazepino and oxazocino quinazolines,” Tetrahedron Letter; 2015:56; 6478-6483. [cited by applicant]
Jin et al., “4′-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(3′,4′, 5′-substituted)anilino-4-hydroxy-8-nitroquinazolines as a novel class of anti-microtubule agents,” Bioorg. Med. Chem. Lett. 2006:5864-5… [cited by applicant]
Zhao et al., “Discovery of substituted 3H-pyrido [2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist,” Bioorg. Med. Chem. Lett. 2020, 127496. [cited by applicant]
Chemical Abstracts STN Registry Database, Record for RN 2578859-71-7, “5-[2-(1-Methyl-1H-pyrazol-4-yl) ethynyl]-4(3H)-quinazolinon”, Entered STN. 2021. [cited by applicant]
Chemical Abstracts STN Registry Database, Record for RN 2398890-74-7, “3,4-Dihydro-N-(2-methylpropyl)-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-5-quinazolinecarboxamide”, Entered STN. 2020. [cited by applicant]
Lu et al., “Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors,” Bioorg Med Chem Lett. Jun. 1, 2014;24(11):2555-9. [cited by applicant]
Wang et al., “Rhodium-Catalyzed Amination and Annulation of Arenes with Anthranils: C—H Activation Assisted by Weakly Coordinating Amides,” Adv. Synth. Catal. Dec. 19, 2017; 359(24):4411-4416. [cited by applicant]
Baker et al., “An Antimalarial Alkaloid From Hydrangea. XVII. Some 5-Substituted Derivatives,” J. Org. Chem. 1952, 17( 1): 164-176. [cited by applicant]
Mishra et al., “The Development of Hsp90ß-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition,” J. Med. Chem. 2021, 64(3): 1545-1557. [cited by applicant]
Stupnikova et al., “Sythesis of Indole Derivitives of Pyrido[2,3-d]Pyrimidine,” Chemistry of Heterocyclic Compounds, 1983, 19(1): 103-106. [cited by applicant]
Bozdag et al., “Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity,” Bioorg Med Chem. 2017, 25(2):677-683. [cited by applicant]
PCT International Search Report and Written Opinon from PCT/US2022/074455, dated Nov. 25, 2022. [cited by applicant]